Covaxin gets the nod for clinical trial here
Covaxin, the Covid-19 vaccine developed by India's Bharat Biotech, got ethical permission to conduct human trial in Bangladesh.
Bangladesh Medical and Research Council (BMRC) has given the permission on July 18, its Chairman Syed Modasser Ali told The Daily Star.
He said International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), the CRO of the vaccine, sought permission for clinical trials a few months ago and the ethical permission for holding the trial was given as all the requirements were fulfilled.
Although BMRC gave ethical permission to bring the vaccine in the country, the CRO (contract research organisation) has to take permission from the Directorate General of Drug Administration, he said.
The BMRC chairman added that they examined not only scientific issues, but also religious, rights and other issues before giving the permission.
The Indian drug maker approached Bangladesh through icddr,b, in mid-January to hold clinical trials of its Covid-19 vaccine in the country. India approved the emergency use authorisation of the vaccine in January.
On June 24, the BMRC approved the Phase III clinical trials of a Chinese vaccine developed by the Institute of Medical Biology and the Chinese Academy of Medical Sciences. And it later approved Bangavax developed by Globe Biotech.
The Bangladesh government has approved Oxford-AstraZeneca's vaccine, Sputnik V, Sinopharm and Sinovac vaccines, Pfizer-BioNTech, Johnson & Johnson and Moderna vaccines for emergency use in Bangladesh.
Comments